Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Phase 1, 2-treatment, 2-period, 2-sequence, Cross-over, Bioequivalence Study Comparing Belumosudil Oral Suspension (Test Formulation) With Belumosudil Tablet (Commercially Available Reference Formulation) in Healthy Adult Male Participants Under Fed Condition

NCT07726914 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07726914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07726914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Phase 1, 2-treatment, 2-period, 2-sequence, Cross-over, Bioequivalence Study Comparing Belumosudil Oral Suspension (Test Formulation) With Belumosudil Tablet (Commercially Available Reference Formulation) in Healthy Adult Male Participants Under Fed Condition
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 6, 2026
Completion date
September 28, 2026
Enrollment
58 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease